Loading…
MAIA
MAIA Biotechnology, Inc.
NYSE American· Healthcare· Biotechnology· CUSIP 552641102
$1.33-3.62%Price as of Aug 29, 18:44 UTC · updated once a day, after the close
Key metrics
- Market cap
- $80.91M
- P/E
- —
- Forward P/E
- 1.2x
- P/B
- 3.9x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.61
- ROE
- -218.68%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.25
- 52-week high
- $3.19
- 52-week low
- $0.87
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -79.3% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.53 | $1.98 | $1.17 | $3.51 | |
| P/B | 27.6x | 39.1x | 16.1x | 49.0x | 4.5x |
| EPS | -$0.70 | -$1.05 | -$1.49 | -$1.75 | |
| ROE | -791.23% | -942.65% | -639.81% | -4140.83% | -185.35% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SERASERA Prognostics Inc | $2.07 | — | 1.4x | — | -45.03% | $81.66M |
| ATHEAlterity Therapeutics Ltd | $4.51 | — | 0.0x | — | -47.02% | $81.75M |
| ZYBTZhengye Biotechnology Holding Ltd | $1.73 | — | 2.2x | — | -25.17% | $81.99M |
| CTORCitius Oncology Inc | $0.78 |
About the company
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
- 13
- Chicago, United States
Company description provided by Yahoo Finance.